Fleury S.A. (BOVESPA:FLRY3) is looking for inorganic growth. Jeane Tsutsui, Chief Executive Officer said, "EBITDA ex business combination expenses pro forma reached BRL 464 million in the quarter, an increase of 14.4% over the second quarter '22 with a 25.2% margin. These figures demonstrate the consistency of our results and give us peace of mind to continue our strategy for organic and inorganic growth and leverage this combination to improve our service offering to patients, physicians, partner, laboratories and health care operators".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.61 BRL | +4.28% | +4.06% | -19.01% |
Mar. 08 | Transcript : Fleury S.A., Q4 2023 Earnings Call, Mar 08, 2024 | |
Mar. 07 | Fleury S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.01% | 1.55B | |
-17.89% | 8.25B | |
+39.20% | 3.57B | |
-39.11% | 2.46B | |
-8.06% | 2.46B | |
-7.35% | 2.38B | |
-12.61% | 1.81B | |
-40.66% | 1.21B | |
+7.56% | 1.11B | |
-15.34% | 1.03B |
- Stock Market
- Equities
- FLRY3 Stock
- News Fleury S.A.
- Fleury Seeks Inorganic Growth